Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Abstract Background Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-posi...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2019-11-01
|
| Col·lecció: | BMC Health Services Research |
| Matèries: | |
| Accés en línia: | http://link.springer.com/article/10.1186/s12913-019-4715-8 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|